ASND•benzinga•
Ascendis Pharma Announced FDA Acceptance For Priority Review Of New Drug Application For TransCon CNP For Children With Achondroplasia And Set Prescription Drug User Fee Act Goal Date Of Nov. 30, 2025 To Complete Review.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga